Suzhou Highfine Biotech Co., Ltd. (SHE:301393)

Suzhou Highfine Biotech Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Cash & Equivalents	550.44	408.66	361.08	1,740	99.32	78.05
Trading Asset Securities	706.88	902.02	1,346	30.76	60	45
Cash & Short-Term Investments	1,257	1,311	1,707	1,770	159.32	123.05
Cash Growth	-26.01%	-23.23%	-3.56%	1011.12%	29.48%	20.56%
Accounts Receivable	232.18	189.26	98.34	63.56	53.42	69.11
Other Receivables	2.03	1.44	11.78	0.49	1.71	3.47
Receivables	234.21	190.7	110.12	64.05	55.12	72.58
Inventory	165.69	161.18	116.7	115	113.45	78.89
Prepaid Expenses	-	-	0.03	-	-	-
Other Current Assets	59.58	27.43	10.1	14.69	24.77	15.72
Total Current Assets	1,717	1,690	1,944	1,964	352.67	290.24
Property, Plant & Equipment	832.35	631.42	320.39	286.46	206.24	142.63
Long-Term Investments	123.88	122.6	-	-	-	-
Goodwill	57.85	57.85	-	-	-	-
Other Intangible Assets	106.32	105.43	66.33	24.02	24.59	25.17
Long-Term Deferred Tax Assets	12.72	11.99	4.39	3.66	3.95	2.37
Long-Term Deferred Charges	0.08	0.35	0.1	0.08	0.26	0.29
Other Long-Term Assets	29.57	34.76	14.14	8.71	12.34	4.4
Total Assets	2,880	2,654	2,350	2,287	600.05	465.09

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Accounts Payable	278.26	77.65	27.21	24.9	36.46	25.59
Accrued Expenses	13.36	25.74	17.95	16.68	23.26	15.24
Short-Term Debt	10.01	10.01	-	-	-	-
Current Portion of Long-Term Debt	1.24	0.03	-	-	-	-
Current Portion of Leases	-	1.38	1.68	0.83	1.04	1.03
Current Income Taxes Payable	10.92	4.42	4.59	3.28	13.94	5.84
Current Unearned Revenue	3.72	0.78	1.38	0.61	0.6	2.34
Other Current Liabilities	32.43	118.86	18.35	19.53	34.04	34.8
Total Current Liabilities	349.95	238.87	71.16	65.84	109.33	84.84
Long-Term Debt	108.42	39.47	-	-	-	-
Long-Term Leases	-	0.44	1.6	0.72	0.39	1.17
Long-Term Unearned Revenue	8.53	9.22	7.65	8.45	7.94	6.52
Long-Term Deferred Tax Liabilities	7.11	7.24	0.94	0.07	0.12	-
Total Liabilities	474.01	295.24	81.35	75.08	117.77	92.53

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Common Stock	108	108	108	108	81	81
Additional Paid-In Capital	1,694	1,690	1,686	1,683	54.79	54.79
Retained Earnings	625.19	583.39	511.55	417.69	345.72	236.6
Treasury Stock	-33.42	-33.42	-42	-	-	-
Comprehensive Income & Other	6.43	4.95	4.44	2.99	0.77	0.18
Total Common Equity	2,401	2,353	2,268	2,212	482.28	372.57
Minority Interest	5.06	6.33	-	-	-	-
Shareholders' Equity	2,406	2,359	2,268	2,212	482.28	372.57
Total Liabilities & Equity	2,880	2,654	2,350	2,287	600.05	465.09

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021
Total Debt	119.67	51.33	3.28	1.56	1.43	2.2
Net Cash (Debt)	1,138	1,259	1,704	1,769	157.9	120.85
Net Cash Growth	-32.94%	-26.10%	-3.66%	1020.18%	30.65%	19.58%
Net Cash Per Share	10.60	11.75	15.75	19.12	1.95	1.50
Filing Date Shares Outstanding	106.5	107.18	106.97	108	81	81
Total Common Shares Outstanding	106.5	107.18	106.97	108	81	81
Working Capital	1,367	1,451	1,873	1,898	243.34	205.4
Book Value Per Share	22.54	21.95	21.20	20.48	5.95	4.60
Tangible Book Value	2,236	2,190	2,202	2,188	457.68	347.4
Tangible Book Value Per Share	21.00	20.43	20.58	20.26	5.65	4.29
Buildings	-	266.28	183.65	171.81	74.32	64.69
Machinery	-	320.25	163.79	76.02	65.92	61.8
Construction In Progress	-	217.39	21.65	72.45	87.92	28.48

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 31, 2026

Data Sources Report a data error